INSMED INC Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- INSMED INC stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $28.01M, a 24.26% decline year-over-year.
- INSMED INC stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $30.27M, a 1.90% increase year-over-year.
- INSMED INC stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $34.63M, a 152.07% increase year-over-year.
- INSMED INC stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $34.41M, a 28.02% increase year-over-year.
- INSMED INC stock issued during period, value, stock options exercised for fiscal 2025 was $135.72M, a 19.85% increase from fiscal 2024.
- INSMED INC stock issued during period, value, stock options exercised for fiscal 2024 was $113.24M, a 515.48% increase from fiscal 2023.
- INSMED INC stock issued during period, value, stock options exercised for fiscal 2023 was $18.40M, a 5.65% decline from fiscal 2022.
- INSMED INC stock issued during period, value, stock options exercised for fiscal 2022 was $19.50M, a 11.50% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $28.01M 10-Q · filed 2026-08-06 | $127.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $30.27M 10-Q · filed 2026-05-07 | $136.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $34.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $135.72M 10-K · filed 2026-02-19 |
| 2025-09-30 | $34.41M 10-Q · filed 2025-10-30 | $114.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $36.98M 10-Q · filed 2026-08-06 | $107.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $29.71M 10-Q · filed 2026-05-07 | $138.90M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $113.24M 10-K · filed 2026-02-19 |
| 2024-09-30 | $26.88M 10-Q · filed 2025-10-30 | $107.22M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $68.57M 10-Q · filed 2025-08-07 | $82.60M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $4.05M 10-Q · filed 2025-05-08 | $21.31M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $7.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $18.40M 10-K · filed 2026-02-19 |
| 2023-09-30 | $2.26M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $7.28M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $1.14M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $19.50M 10-K · filed 2025-02-20 | |
| 2021-12-31 | $22.04M 10-K · filed 2024-02-22 | |
| 2020-12-31 | $26.07M 10-K · filed 2023-02-23 | |
| 2020-03-31 | $2.43M 10-Q · filed 2020-04-30 | $19.08M derived: sum of 4 quarters · filed 2022-02-17 |
| 2019-12-31 | $4.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $19.70M 10-K · filed 2022-02-17 |
| 2019-09-30 | $1.46M 10-Q · filed 2019-10-30 | $17.39M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $10.46M 10-Q · filed 2019-08-01 | $16.53M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $3.05M 10-Q · filed 2020-04-30 | $11.72M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $8.81M 10-K · filed 2021-02-25 |
| 2018-09-30 | $604.00K 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $5.64M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $142.00K 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $3.43M 10-K · filed 2020-02-25 | |
| 2016-12-31 | $1.08M 10-K · filed 2019-02-22 | |
| 2015-12-31 | $5.11M 10-K · filed 2018-02-23 | |
| 2014-12-31 | $1.73M 10-K · filed 2017-02-23 | |
| 2013-12-31 | $1.63M 10-K · filed 2016-02-25 | |
| 2012-12-31 | $214.00K 10-K · filed 2015-02-27 | |
| 2011-12-31 | $32.00K 10-K · filed 2014-03-06 | |
| 2009-12-31 | $580.00K 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |